Back to Newsroom
Back to Newsroom

The Pain Treatment Center of Ocala Recognized as Center of Excellence

Tuesday, 10 September 2019 11:50 AM

StimWave Technologies

National program highlights innovative, minimally invasive, non-opioid treatment option for chronic pain patients

OCALA, FL / ACCESSWIRE / September 10, 2019 / Stimwave Technologies, the leading innovator of wireless medical pain relief implant bioelectric technology, announced today that it named The Pain Treatment Center of Ocala, founded by Dr. Stephen Pyles, a Stimwave Center of Excellence as part of its recently launched national program to spotlight physicians that provide unparalleled commitment and dedication to patient outcomes.

Click here to view the full press release, including media-ready images, downloadable resources, and more.

StimWave Technologies, Tuesday, September 10, 2019, Press release picture

StimWave Technologies, Tuesday, September 10, 2019, Press release picture

About The Pain Treatment Center of Ocala

Dr. Pyles started The Pain Treatment Center of Ocala in 1985 with the goal of providing a location for physicians and their patients to receive quality efficient diagnosis and treatment of chronic pain conditions. Most all chronic pain syndromes are treated at The Pain Treatment Center of Ocala; however, the practice is primarily an "interventional" type of pain management program with an emphasis on using neuromodulation techniques such as peripheral nerve stimulation and spinal cord stimulation. Dr. Pyles has both a national and an international reputation as an innovator in the field of neuromodulation. For more information visit www.paintreatmentcenters.net.

About Stimwave

Stimwave Technologies Incorporated is a privately held medical device company engaged in the development, manufacture, and commercialization of wirelessly powered, injectable, microtechnology neurostimulators, providing patients with a convenient, safe, minimally invasive, and highly cost-effective pain management solution that is easily incorporated into their daily lives. Stimwave’s goal is to evolve its patented, cutting-edge platform into the default for neuromodulation, increasing the accessibility for patients worldwide while lowering the economic burden of pain management. www.stimwave.com.

Investor Contact

Mike Vallie
[email protected]
443-213-0499

Media Contact

Darcie Robinson, Westwicke, an ICR company
[email protected]
203-919-7905

SOURCE: Stimwave Technologies

Topic:
Company Update
Back to newsroom
Back to Newsroom
Share by: